An Open-Label Study of Lumateperone in Pediatric Subjects with Schizophrenia

  • Ages 13-17
  • Diagnosis or symptoms of schizophrenia without catatonia
  • Must be able to swallow a capsule and comply with all study procedures
  • Must maintain an outpatient status for the duration of the study
  • If you have history of medical issues such as seizures, blood disorders, or other major health conditions you may not qualify for this trial
  • Method of Administration :  Oral / Capsule
    • Length/Duration: 56 monthly visits
    • Location:  721 North Magnolia Avenue, Orlando FL 32803
    • Compensation: $100 / visit
    • Participants may:
      • See a doctor or medical staff at no cost
      • Have access to trial medications
      • Receive compensation for time and travel

Learn More About Participating in a Study

  • This field is for validation purposes and should be left unchanged.